Scarica l'app Stockscreener
19.41
0.36%
0.07
Dopo l'orario di chiusura:
18.89
-0.52
-2.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Will Castle Biosciences Inc. outperform tech stocksMax Yield Daily Selections - mustnews.co.kr
Castle Biosciences Updates Bylaws for Improved Governance - TipRanks
CSTL SEC FilingsCastle Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Price Clustering Detected in Castle Biosciences Inc. StockExit Ready Momentum Stock Watchlist Expanded - beatles.ru
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Castle Biosciences (CSTL) and Regeneron (REGN) - The Globe and Mail
Castle Biosciences Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Castle Biosciences Reports Strong Q2 2025 Results - TipRanks
Barrett Business Reports Q2 GAAP EPS of $0.70, Beating Estimates by $0.01 - AInvest
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences Maintains Strong Buy Rating with $32 Price Target - AInvest
Castle Biosciences Raises Revenue Guidance Amid Growth and Challenges - AInvest
Robert W. Baird Sticks to Its Buy Rating for Castle Biosciences (CSTL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie, Castle Biosciences, and Regeneron - AInvest
Castle Biosciences’ Earnings Call: Growth Amid Challenges - TipRanks
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates - MSN
Castle Biosciences Reports Strong Q2 2025 Financial Results - MSN
Castle Biosciences Soars 22.52% on Strong Q2 Earnings - AInvest
Castle Biosciences Q2 2025 Earnings Call Highlights: Strong Revenue Growth Despite Challenges - AInvest
Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance
Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Castle Biosciences Q2 2025 Earnings Exceed Expectations with $86.2M Revenue, $0.16 EPS, and Strong Gross Margin of 77% - AInvest
Castle Biosciences: A Strategic Bet on Personalized Oncology Diagnostics - AInvest
Transcript : Castle Biosciences, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
Castle Biosciences Outpaces Estimates And Ups Forecast - Finimize
Castle Biosciences Outpaces Expectations With Bright Forecast - Finimize
Earnings call transcript: Castle Biosciences Q2 2025 beats EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Castle Biosciences Q2 2025 beats EPS forecast - Investing.com
Medical testing provider Castle Bio raises annual revenue guidance - MarketScreener
Castle Biosciences Q2 2025 slides: Test volume surges 33% amid declining margins - Investing.com India
Castle Biosciences Reports Second Quarter 2025 Results - The Manila Times
Shareholders in Castle Biosciences (NASDAQ:CSTL) have lost 65%, as stock drops 10% this past week - simplywall.st
What drives Castle Biosciences Inc. stock priceMaximize gains with strategic stock entries - Jammu Links News
What is the dividend policy of Castle Biosciences Inc. stockHigh-octane gains - Jammu Links News
What are analysts’ price targets for Castle Biosciences Inc. in the next 12 monthsMaximize portfolio returns with smart trading - Jammu Links News
What catalysts could drive Castle Biosciences Inc. stock higher in 2025Invest smarter with expert trading signals - Jammu Links News
What are Castle Biosciences Inc. company’s key revenue driversOutstanding growth strategies - Jammu Links News
Should I hold or sell Castle Biosciences Inc. stock in 2025Phenomenal capital gains - Jammu Links News
What institutional investors are buying Castle Biosciences Inc. stockMaximize your portfolio’s earning potential - Jammu Links News
When is Castle Biosciences Inc. stock expected to show significant growthRapid portfolio appreciation - Jammu Links News
How volatile is Castle Biosciences Inc. stock compared to the marketGrow your wealth steadily and securely - Jammu Links News
How many analysts rate Castle Biosciences Inc. as a “Buy”Free Stock Selection - Jammu Links News
Castle Biosciences Q2 Earnings Preview: Analysts Expect $-0.50 EPS - AInvest
Castle Biosciences CSTL Q2 2025 Earnings Preview Upside Potential on Raised Revenue Forecast - AInvest
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 26% - 富途牛牛
Published on: 2025-07-30 02:23:31 - metal.it
The True Test of Success - thebossmagazine.com
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Healthcare Innovator Castle Biosciences Reveals Latest Growth Strategy at Major Investment Conference - Stock Titan
What Technical Tools Say About Castle Biosciences Inc. RecoveryConsistent Income Focused Trade List Analyzed - metal.it
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline - Yahoo Finance
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - MSN
3.96%
1.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):